Hauptdiskussion WKN: A2PEYK ISIN: US73730P1084 Kürzel: PSTX Forum: Aktien User: Schorsch11

https://www.fiercebiotech.com/biotech/poseida-shares-plunge-after-death-solid-car-t-trial-hold

Net Losses Net losses were $30.4 million and $59.2 million for the three and six months ended June 30, 2020, respectively, and $28.6 million and $42.0 million for the three and six months ended June 30, 2019, respectively.  Cash Position As of June 30, 2020, we had cash, cash equivalents and short-term investments of $167.1 million. Net proceeds from the Company's IPO, which closed in July 2020, were $204.8 million

Rebound-Kandidat: Poseida Therapeutics, Inc. (NASDAQ:PSTX) shares closed the week down 34% to $8.61 on news its Phase 1 trial of P-PSMA-101 in metastatic castrate resistant prostate cancer patients has been placed on clinical hold due to a patient death arising from hepatic failure.